|
1
|
Ganly I, Patel S and Shah J: Early stage
squamous cell cancer of the oral tongue - clinicopathologic
features affecting outcome. Cancer. 118:101–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zini A, Czerninski R and Sgan-Cohen HD:
Oral cancer over four decades. Epidemiology, trends, histology and
survival by anatomical sites. J Oral Pathol Med. 39:299–305. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Warnakulasuriya S: Living with oral
cancer: Epidemiology with particular reference to prevalence and
life-style changes that influence survival. Oral Oncol. 46:407–410.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Silverman S Jr, Gorsky M and Lozada F:
Oral leukoplakia and malignant transformation. A follow-up study of
257 patients. Cancer. 53:563–568. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papadimitrakopoulou VA, Hong WK, Lee JS,
Martin JW, Lee JJ, Batsakis JG and Lippman SM: Low-dose
isotretinoin versus beta-carotene to prevent oral carcinogenesis:
Long-term follow-up. J Natl Cancer Inst. 89:257–258. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fan XC and Steitz JA: HNS, a
nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci
USA. 95:15293–15298. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rebane A, Aab A and Steitz JA: Transportin
1 and 2 are redundant nuclear import factors for hnRNP A1 and HuR.
RNA. 10:590–599. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brennan CM, Gallouzi IE and Steitz JA:
Protein ligands to HuR modulate its interaction with target mRNAs
in vivo. J Cell Biol. 151:1–14. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Erkinheimo TL, Lassus H, Sivula A,
Sengupta S, Furneaux H, Hla T, Haglund C, Butzow R and Ristimäki A:
Cytoplasmic HuR expression correlates with poor outcome and with
cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer
Res. 63:7591–7594. 2003.PubMed/NCBI
|
|
10
|
Denkert C, Weichert W, Pest S, Koch I,
Licht D, Köbel M, Reles A, Sehouli J, Dietel M and Hauptmann S:
Overexpression of the embryonic-lethal abnormal vision-like protein
HuR in ovarian carcinoma is a prognostic factor and is associated
with increased cyclooxygenase 2 expression. Cancer Res. 64:189–195.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kahn HJ and Marks A: A new monoclonal
antibody, D2-40, for detection of lymphatic invasion in primary
tumors. Lab Invest. 82:1255–1257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Inoue H, Miyazaki Y, Kikuchi K, Yoshida N,
Ide F, Ohmori Y, Tomomura A, Sakashita H and Kusama K: Podoplanin
expression during dysplasia-carcinoma sequence in the oral cavity.
Tumor Biol. 33:181–194. 2012. View Article : Google Scholar
|
|
13
|
Saintigny P, El-Naggar AK,
Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong
WK, Lippman SM and Mao L: DeltaNp63 over expression, alone and in
combination with other biomarkers, predicts the development of oral
cancer in patients with leukoplakia. Clin Cancer Res. 15:6284–6291.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawaguchi H, El-Naggar A,
Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong
WK, Lippman SM and Mao L: Podoplanin: A novel marker for oral
cancer risk in patients with oral premalignancy. J Clin Oncol.
26:354–360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wicki A and Christofori G: The potential
role of podoplanin in tumour invasion. Br J Cancer. 96:1–5. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martín-Villar E, Scholl FG, Gamallo C,
Yuritta MM, Muñoz-Guerra M, Cruces J and Quintanilla M:
Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a
small membrane mucin induced in oral squamous cell carcinomas. Int
J Cancer. 113:899–910. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mithani SK, Mydlarz WK, Grumbione FL,
Smith IM and Califano JA: Molecular genetics of premalignant oral
lesions. Oral Diseases. 13:126–133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Habiba U, Kitamura T, Yanagawa-Matsuda A,
Hida K, Higashino F, Ohiro Y, Totsuka Y and Shindoh M: Cytoplasmic
expression of HuR may be a valuable diagnostic tool for determining
the potential for malignant transformation of oral verrucous
borderline lesions. Oncol Rep. 31:1547–1554. 2014.PubMed/NCBI
|
|
19
|
Cho NP, Han HS, Soh Y, Lee KY and Son HJ:
Cytoplasmic HuR over-expression is associated with increased
cyclooxygenase-2 expression in laryngeal squamous cell carcinomas.
Pathology. 39:545–550. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cho NP, Han HS, Soh Y and Son HJ:
Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR
expression in salivary mucoepidermoid carcinoma but not in
pleomorphic adenoma. J Oral Pathol Med. 36:297–303. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heinonen M, Bono P, Narko K, Chang SH,
Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C and Ristimäki A:
Cytoplasmic HuR expression is a prognostic factor in invasive
ductal breast carcinoma. Cancer Res. 65:2157–2161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niesporek S, Kristiansen G, Thoma A,
Weichert W, Noske A, Buckendahl AC, Jung K, Stephan C, Dietel M and
Denkert C: Expression of the ELAV-like protein HuR in human
prostate carcinoma is an indicator of disease relapse and linked to
COX-2 expression. Int J Oncol. 32:341–347. 2008.PubMed/NCBI
|
|
23
|
Gallouzi IE and Steitz JA: Delineation of
mRNA export pathways by the use of cell-permeable peptides.
Science. 294:1895–1901. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hasegawa H, Kakuguchi W, Kuroshima T,
Kitamura T, Tanaka S, Kitagawa Y, Totsuka Y, Shindoh M and
Higashino F: HuR is exported to the cytoplasm in oral cancer cells
in a different manner from that of normal cells. Br J Cancer.
100:1943–1948. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan P, Temam S, El-Naggar A, Zhou X, Liu
DD, Lee JJ and Mao L: Overexpressin of podoplanin in oral cancer
and its association with poor clinical outcome. Cancer.
107:563–569. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kreppel M, Scheer M, Drebber U, Ritter L
and Zöller JE: Impact of podoplanin expression in oral squamous
cell carcinoma: Clinical and histopathologic correlations. Virchows
Arch. 456:473–482. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Villaret A Bolzoni, Schreiber A, Facchetti
F, Fisogni S, Lonardi S, Lombardi D, Cocco D, de Zinis LO Redaelli
and Nicolai P: Immunostaining patterns of CD31 and podoplanin in
previously untreated advanced oral/oropharyngeal cancer: Prognostic
implications. Head neck. 32:786–792. 2010.PubMed/NCBI
|
|
28
|
Holmstrup P, Vedtofte P, Reibel J and
Stoltze K: Long term treatment outcome of oral premalignant
lesions. Oral Oncol. 42:461–474. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Karrabul A, Reibel J, Therkildsen MH,
Praetorius F, Nielsen HW and Dabelsteen E: Observer variability in
the histologic assessment of oral premalignant lesions. J Pathol
Med. 24:198–200. 1995. View Article : Google Scholar
|
|
30
|
Abbey LM, Kaugars GE, Gunsolley JC, Burns
JC, Page DG, Svirsky JA, Eisenberg E, Krutchkoff DJ and Cushing M:
Intraexaminer and interexaminer reliability in diagnosis of oral
epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 80:188–191. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
de Vicente JC, Rodrigo JP,
Rodriguez-Santamarta T, Lequerica-Fernández P, Allonca E and
Garcia-Pedrero JM: Podoplanin expression in oral leukoplakia:
Tumorigenic role. Oral Oncol. 49:598–603. 2013. View Article : Google Scholar : PubMed/NCBI
|
